Align Technology Competitors

West Pharmaceutical Services (NYSE:WST) and Align Technology (NASDAQ:ALGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Insider and Institutional Ownership

92.6% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 1.6% of West Pharmaceutical Services shares are held by company insiders. Comparatively, 1.2% of Align Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares West Pharmaceutical Services and Align Technology's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares West Pharmaceutical Services and Align Technology's gross revenue, earnings per share (EPS) and valuation.

Align Technology has higher revenue and earnings than West Pharmaceutical Services. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

West Pharmaceutical Services has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for West Pharmaceutical Services and Align Technology, as reported by MarketBeat.

West Pharmaceutical Services presently has a consensus price target of $310.00, indicating a potential upside of 11.47%. Align Technology has a consensus price target of $475.4615, indicating a potential downside of 15.58%. Given West Pharmaceutical Services' stronger consensus rating and higher probable upside, equities research analysts plainly believe West Pharmaceutical Services is more favorable than Align Technology.

Summary

Align Technology beats West Pharmaceutical Services on 9 of the 14 factors compared between the two stocks.

The Cooper Companies (NYSE:COO) and Align Technology (NASDAQ:ALGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Insider and Institutional Ownership

95.8% of The Cooper Companies shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 1.4% of The Cooper Companies shares are held by company insiders. Comparatively, 1.2% of Align Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares The Cooper Companies and Align Technology's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares The Cooper Companies and Align Technology's gross revenue, earnings per share (EPS) and valuation.

Align Technology has lower revenue, but higher earnings than The Cooper Companies. The Cooper Companies is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

The Cooper Companies has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for The Cooper Companies and Align Technology, as reported by MarketBeat.

The Cooper Companies presently has a consensus price target of $360.0769, indicating a potential downside of 7.18%. Align Technology has a consensus price target of $475.4615, indicating a potential downside of 15.58%. Given The Cooper Companies' stronger consensus rating and higher probable upside, equities research analysts plainly believe The Cooper Companies is more favorable than Align Technology.

DENTSPLY SIRONA (NASDAQ:XRAY) and Align Technology (NASDAQ:ALGN) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Insider and Institutional Ownership

96.0% of DENTSPLY SIRONA shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 0.5% of DENTSPLY SIRONA shares are held by company insiders. Comparatively, 1.2% of Align Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares DENTSPLY SIRONA and Align Technology's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares DENTSPLY SIRONA and Align Technology's gross revenue, earnings per share (EPS) and valuation.

Align Technology has lower revenue, but higher earnings than DENTSPLY SIRONA. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

DENTSPLY SIRONA has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for DENTSPLY SIRONA and Align Technology, as reported by MarketBeat.

DENTSPLY SIRONA presently has a consensus price target of $55.00, indicating a potential downside of 7.20%. Align Technology has a consensus price target of $475.4615, indicating a potential downside of 15.58%. Given DENTSPLY SIRONA's higher probable upside, equities research analysts plainly believe DENTSPLY SIRONA is more favorable than Align Technology.

Summary

Align Technology beats DENTSPLY SIRONA on 11 of the 14 factors compared between the two stocks.

Quidel (NASDAQ:QDEL) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Quidel and Align Technology, as reported by MarketBeat.

Quidel presently has a consensus price target of $245.60, indicating a potential upside of 52.27%. Align Technology has a consensus price target of $475.4615, indicating a potential downside of 15.58%. Given Quidel's higher probable upside, equities research analysts plainly believe Quidel is more favorable than Align Technology.

Insider and Institutional Ownership

84.0% of Quidel shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 14.1% of Quidel shares are held by company insiders. Comparatively, 1.2% of Align Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Quidel and Align Technology's gross revenue, earnings per share (EPS) and valuation.

Align Technology has higher revenue and earnings than Quidel. Quidel is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quidel and Align Technology's net margins, return on equity and return on assets.

Volatility & Risk

Quidel has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500.

Summary

Align Technology beats Quidel on 12 of the 14 factors compared between the two stocks.

Align Technology (NASDAQ:ALGN) and Haemonetics (NYSE:HAE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations.

Insider & Institutional Ownership

85.8% of Align Technology shares are owned by institutional investors. Comparatively, 96.2% of Haemonetics shares are owned by institutional investors. 1.2% of Align Technology shares are owned by company insiders. Comparatively, 1.6% of Haemonetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Align Technology and Haemonetics' gross revenue, earnings per share (EPS) and valuation.

Align Technology has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Align Technology and Haemonetics, as reported by MarketBeat.

Align Technology currently has a consensus price target of $475.4615, indicating a potential downside of 15.58%. Haemonetics has a consensus price target of $144.80, indicating a potential upside of 15.62%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts plainly believe Haemonetics is more favorable than Align Technology.

Profitability

This table compares Align Technology and Haemonetics' net margins, return on equity and return on assets.

Risk and Volatility

Align Technology has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.

Summary

Align Technology beats Haemonetics on 9 of the 14 factors compared between the two stocks.

STAAR Surgical (NASDAQ:STAA) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, analyst recommendations and risk.

Earnings and Valuation

This table compares STAAR Surgical and Align Technology's revenue, earnings per share (EPS) and valuation.

Align Technology has higher revenue and earnings than STAAR Surgical. Align Technology is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

85.4% of STAAR Surgical shares are owned by institutional investors. Comparatively, 85.8% of Align Technology shares are owned by institutional investors. 3.9% of STAAR Surgical shares are owned by insiders. Comparatively, 1.2% of Align Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares STAAR Surgical and Align Technology's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and target prices for STAAR Surgical and Align Technology, as provided by MarketBeat.

STAAR Surgical presently has a consensus target price of $68.50, indicating a potential downside of 33.98%. Align Technology has a consensus target price of $475.4615, indicating a potential downside of 15.58%. Given Align Technology's stronger consensus rating and higher possible upside, analysts plainly believe Align Technology is more favorable than STAAR Surgical.

Volatility & Risk

STAAR Surgical has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Summary

Align Technology beats STAAR Surgical on 11 of the 14 factors compared between the two stocks.